Cristina Popa
@nephroseeker.medsky.social
🩺 Nephrologist = kidney philosopher
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC editor-in-chief
📍@KIreportsbsky.social
📍ERAkidney #ERA26 social media co-leader
#NephSky #MedSky
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC editor-in-chief
📍@KIreportsbsky.social
📍ERAkidney #ERA26 social media co-leader
#NephSky #MedSky
Reposted by Cristina Popa
✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award
👇Here's a reminder of previous winners
📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form
www.nephjc.com/news/...
#NephJC
👇Here's a reminder of previous winners
📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form
www.nephjc.com/news/...
#NephJC
February 11, 2026 at 2:55 AM
✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award
👇Here's a reminder of previous winners
📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form
www.nephjc.com/news/...
#NephJC
👇Here's a reminder of previous winners
📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form
www.nephjc.com/news/...
#NephJC
Reposted by Cristina Popa
honestly not sure!
remember RASi effect in transplant is not as impressive (ahem pubmed.ncbi.nlm.nih.gov/27712852/ in @ajkd.bsky.social ) despite @kdigo.org guidelines
#NephJC
remember RASi effect in transplant is not as impressive (ahem pubmed.ncbi.nlm.nih.gov/27712852/ in @ajkd.bsky.social ) despite @kdigo.org guidelines
#NephJC
Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials - PubMed
This analysis neither supports nor refutes the hypothesis that RAS blockade improves clinical outcomes in kidney transplant recipients. A trial with more than 10,000 patients would be needed to definitively answer whether RAS blockade reduces transplant loss in this population. In the meantime, clin …
pubmed.ncbi.nlm.nih.gov
February 11, 2026 at 2:16 AM
honestly not sure!
remember RASi effect in transplant is not as impressive (ahem pubmed.ncbi.nlm.nih.gov/27712852/ in @ajkd.bsky.social ) despite @kdigo.org guidelines
#NephJC
remember RASi effect in transplant is not as impressive (ahem pubmed.ncbi.nlm.nih.gov/27712852/ in @ajkd.bsky.social ) despite @kdigo.org guidelines
#NephJC
Reposted by Cristina Popa
Markers of endothelial and podocyte stress in structurally normal kidney transplants! pubmed.ncbi.nlm.nih.gov/34952098/
#NephJC
#NephJC
Glomerular endothelial cell-podocyte stresses and crosstalk in structurally normal kidney transplants - PubMed
Increased podocyte detachment begins immediately after kidney transplantation and is associated with long-term allograft failure. We hypothesized that cell-specific transcriptional changes in podocytes and glomerular endothelial cells after transplantation would offer mechanistic insights into the p …
pubmed.ncbi.nlm.nih.gov
February 11, 2026 at 2:14 AM
Markers of endothelial and podocyte stress in structurally normal kidney transplants! pubmed.ncbi.nlm.nih.gov/34952098/
#NephJC
#NephJC
Reposted by Cristina Popa
The simplest rule is to be kind and inclusive while you use your wit! Here are #NephJC values, summarized by Sinead Stoneman
February 11, 2026 at 2:01 AM
The simplest rule is to be kind and inclusive while you use your wit! Here are #NephJC values, summarized by Sinead Stoneman
Reposted by Cristina Popa
⏰30 min before the #NephJC chat
There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC
Are you pumped to know how and how well #Flozins work in transplanted patients?
Let's deep dive in a few minutes!
There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC
Are you pumped to know how and how well #Flozins work in transplanted patients?
Let's deep dive in a few minutes!
February 11, 2026 at 1:30 AM
Reposted by Cristina Popa
And in honor of Bad Bunny's win at the Super Bowl 🏆,
here is the INFINITI VA en Espanol #NephSky
www.nephjc.com/news/2026/2/8/infiniti-el-resumen-visual
here is the INFINITI VA en Espanol #NephSky
www.nephjc.com/news/2026/2/8/infiniti-el-resumen-visual
INFINITI: El Resumen Visual — NephJC
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 e...
www.nephjc.com
February 9, 2026 at 12:37 PM
And in honor of Bad Bunny's win at the Super Bowl 🏆,
here is the INFINITI VA en Espanol #NephSky
www.nephjc.com/news/2026/2/8/infiniti-el-resumen-visual
here is the INFINITI VA en Espanol #NephSky
www.nephjc.com/news/2026/2/8/infiniti-el-resumen-visual
Reposted by Cristina Popa
Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
INFINITI: The Visual Abstract — NephJC
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in...
www.nephjc.com
February 9, 2026 at 12:40 PM
Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
Reposted by Cristina Popa
Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
www.nephjc.com
February 8, 2026 at 11:25 PM
Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
Reposted by Cristina Popa
New Podcast: Martin R. Prince discusses the findings of his study, “Automatically Measuring Kidney, Liver, and Cyst Volumes in Autosomal Dominant Polycystic Kidney Disease". Listen here: kidney.pub/JPOD0904
February 5, 2026 at 5:00 PM
New Podcast: Martin R. Prince discusses the findings of his study, “Automatically Measuring Kidney, Liver, and Cyst Volumes in Autosomal Dominant Polycystic Kidney Disease". Listen here: kidney.pub/JPOD0904
Reposted by Cristina Popa
In the Literature by Georgina Gyarmati:
Are Mother Glomeruli in Good or Bad Company?
bit.ly/4tchcUN (FREE)
Are Mother Glomeruli in Good or Bad Company?
bit.ly/4tchcUN (FREE)
February 1, 2026 at 11:00 PM
In the Literature by Georgina Gyarmati:
Are Mother Glomeruli in Good or Bad Company?
bit.ly/4tchcUN (FREE)
Are Mother Glomeruli in Good or Bad Company?
bit.ly/4tchcUN (FREE)
Reposted by Cristina Popa
telegram-based paper mill
retractionwatch.com/2026/01/26/s... on @retractionwatch.com
$165 for first author,
$110 for second author,
and $55 for the remaining slots
welcome to academic publishing!
retractionwatch.com/2026/01/26/s... on @retractionwatch.com
$165 for first author,
$110 for second author,
and $55 for the remaining slots
welcome to academic publishing!
Study is stolen, sold, published. Now the victim is accused of plagiarism
The year 2026 did not start off kindly for Vijayalakshmi S, an economics researcher at RV University in Bengaluru, India. She received a rejection letter from a journal noting that a paper of hers …
retractionwatch.com
February 1, 2026 at 5:01 PM
telegram-based paper mill
retractionwatch.com/2026/01/26/s... on @retractionwatch.com
$165 for first author,
$110 for second author,
and $55 for the remaining slots
welcome to academic publishing!
retractionwatch.com/2026/01/26/s... on @retractionwatch.com
$165 for first author,
$110 for second author,
and $55 for the remaining slots
welcome to academic publishing!
Reposted by Cristina Popa
super interesting mechanistic study
effect of potassium supplement on natriuresis, with and without lisinopril
in patients with and without CKD
academic.oup.com/ndt/article-...
effect of potassium supplement on natriuresis, with and without lisinopril
in patients with and without CKD
academic.oup.com/ndt/article-...
January 30, 2026 at 10:33 PM
super interesting mechanistic study
effect of potassium supplement on natriuresis, with and without lisinopril
in patients with and without CKD
academic.oup.com/ndt/article-...
effect of potassium supplement on natriuresis, with and without lisinopril
in patients with and without CKD
academic.oup.com/ndt/article-...
Reposted by Cristina Popa
January 31, 2026 at 11:00 PM
Reposted by Cristina Popa
#TopNephrology stories of 2025
the podcast is out: www.nephjc.com/freelyfilter...
with @kidneyboy.bsky.social @captainchloride.bsky.social @medpeedskidneys.bsky.social @annagaddy.bsky.social @vipvargh.bsky.social @brianrifkin.bsky.social & @nephroseeker.medsky.social
the podcast is out: www.nephjc.com/freelyfilter...
with @kidneyboy.bsky.social @captainchloride.bsky.social @medpeedskidneys.bsky.social @annagaddy.bsky.social @vipvargh.bsky.social @brianrifkin.bsky.social & @nephroseeker.medsky.social
FF 89 Top Stories of 2025 — NephJC
I know 2026 feels like it ihas been here for months, but only a few weeks ago we were celebrating the nephrology accomplishments of 2025. The New Filtrate came together to review the year.
www.nephjc.com
January 31, 2026 at 7:08 PM
Reposted by Cristina Popa
Reposted by Cristina Popa
T2g
Secondary outcomes (Appropriate ICD therapy/VT)
👉15.3% high-normal K
👉 20.3% standard care
🎯HR 0.75 (95% CI 0.57–0.98)
a clear reduction in dangerous arrhythmias #NephJC
Secondary outcomes (Appropriate ICD therapy/VT)
👉15.3% high-normal K
👉 20.3% standard care
🎯HR 0.75 (95% CI 0.57–0.98)
a clear reduction in dangerous arrhythmias #NephJC
January 28, 2026 at 2:35 AM
T2g
Secondary outcomes (Appropriate ICD therapy/VT)
👉15.3% high-normal K
👉 20.3% standard care
🎯HR 0.75 (95% CI 0.57–0.98)
a clear reduction in dangerous arrhythmias #NephJC
Secondary outcomes (Appropriate ICD therapy/VT)
👉15.3% high-normal K
👉 20.3% standard care
🎯HR 0.75 (95% CI 0.57–0.98)
a clear reduction in dangerous arrhythmias #NephJC
Reposted by Cristina Popa
Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
POTCAST- K+ Pop and Arrhythmia Drop — NephJC
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
www.nephjc.com
January 26, 2026 at 9:47 PM
Oh, the weather outside is frightful 🥶🥶
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
But #NephJC is so delightful,
and since you've no place to go #NephSky...
Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky
Summary by @shelliefravel.bsky.social @salinesolut.bsky.social
www.nephjc.com/news/potcast
Reposted by Cristina Popa
5 reasons to publish with KICR
www.theisn.org/blog/2026/01...
@theisn.org @arvindcanchi.bsky.social
#NephSky
www.theisn.org/blog/2026/01...
@theisn.org @arvindcanchi.bsky.social
#NephSky
Five compelling reasons to submit to Kidney International Case Reports™ - International Society of Nephrology
www.theisn.org
January 27, 2026 at 12:05 PM
5 reasons to publish with KICR
www.theisn.org/blog/2026/01...
@theisn.org @arvindcanchi.bsky.social
#NephSky
www.theisn.org/blog/2026/01...
@theisn.org @arvindcanchi.bsky.social
#NephSky
Reposted by Cristina Popa
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones?
🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social
www.nephjc.com/news/2026/1/...
🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social
www.nephjc.com/news/2026/1/...
January 26, 2026 at 9:13 AM
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones?
🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social
www.nephjc.com/news/2026/1/...
🎨Resumen visual por @jeyakumarmeyyappan.bsky.social
✍️Traducido por @dramiliflores.bsky.social
www.nephjc.com/news/2026/1/...
Reposted by Cristina Popa
🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations?
🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social
⏰ #NephJC chat on Jan 27, 9 pm EST
www.nephjc.com/news/2026/1/...
🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social
⏰ #NephJC chat on Jan 27, 9 pm EST
www.nephjc.com/news/2026/1/...
January 26, 2026 at 9:05 AM
🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations?
🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social
⏰ #NephJC chat on Jan 27, 9 pm EST
www.nephjc.com/news/2026/1/...
🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social
⏰ #NephJC chat on Jan 27, 9 pm EST
www.nephjc.com/news/2026/1/...
Reposted by Cristina Popa
Our large kidney transcriptomic dataset of #ANCA #glomerulonephritis is now publicly available (www.ncbi.nlm.nih.gov/geo/query/ac...). Used to describe a strong renal interferon signature and a prognosis signature outperforming current classifications (links below). I hope it will be useful! 🚀
January 22, 2026 at 7:54 AM
Our large kidney transcriptomic dataset of #ANCA #glomerulonephritis is now publicly available (www.ncbi.nlm.nih.gov/geo/query/ac...). Used to describe a strong renal interferon signature and a prognosis signature outperforming current classifications (links below). I hope it will be useful! 🚀
Reposted by Cristina Popa
1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
January 16, 2026 at 9:16 PM
1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit.
www.nejm.org/doi/full/10....
Reposted by Cristina Popa
9’/10
We wouldn’t have a complete view on C3GN treatment if we didn’t discuss iptacopan and the APPEAR C3G trial
Read the #NephJCshort by @nephroseeker.medsky.social and @drpallaviprasad.bsky.social
www.nephjc.com/news/2026/1/...
We wouldn’t have a complete view on C3GN treatment if we didn’t discuss iptacopan and the APPEAR C3G trial
Read the #NephJCshort by @nephroseeker.medsky.social and @drpallaviprasad.bsky.social
www.nephjc.com/news/2026/1/...
A ray of hope APPEARS for C3G — NephJC
The NephJC shorts on APPEAR-G3C randomized controlled trial: iptacopan in C3GN
www.nephjc.com
January 16, 2026 at 9:16 PM
9’/10
We wouldn’t have a complete view on C3GN treatment if we didn’t discuss iptacopan and the APPEAR C3G trial
Read the #NephJCshort by @nephroseeker.medsky.social and @drpallaviprasad.bsky.social
www.nephjc.com/news/2026/1/...
We wouldn’t have a complete view on C3GN treatment if we didn’t discuss iptacopan and the APPEAR C3G trial
Read the #NephJCshort by @nephroseeker.medsky.social and @drpallaviprasad.bsky.social
www.nephjc.com/news/2026/1/...
Reposted by Cristina Popa
10/10 ➡️Next up: 1/27/26, 9pm EST #NephJC POTCAST trial!
www.nejm.org/doi/abs/10.1...
👋thread by @thekidneywhisperer.bsky.social
www.nejm.org/doi/abs/10.1...
👋thread by @thekidneywhisperer.bsky.social
Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias | NEJM
Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular
arrhythmias among patients with cardiovascular disease. An assessment of a strategy
of actively increasing p...
www.nejm.org
January 16, 2026 at 9:16 PM
10/10 ➡️Next up: 1/27/26, 9pm EST #NephJC POTCAST trial!
www.nejm.org/doi/abs/10.1...
👋thread by @thekidneywhisperer.bsky.social
www.nejm.org/doi/abs/10.1...
👋thread by @thekidneywhisperer.bsky.social